News
The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...
BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...
Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...
BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...
FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results